MWNA
SRNE

Marshall Wace North America’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Marshall Wace North America’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-115,009
Closed -$230K – 1580
2017
Q2 		$230K Buy
+115,009
New +$224K ﹤0.01% 1205

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace North America's SRNE Position: Q3 2017 in Review

Marshall Wace North America sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2017, closing a stake of 115,009 shares — an estimated $230K sold.

Marshall Wace North America first reported a position in SRNE in Q2 2017 and held it in 1 quarter. The position peaked at $230K in Q2 2017. 37 funds tracked by Wall St. Rank hold SRNE as of Q3 2017.

  • Marshall Wace North America reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Marshall Wace North America sold 115,009 Sorrento Therapeutics, Inc. shares in Q3 2017, an estimated $230K.
  • Marshall Wace North America first reported a position in Sorrento Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Marshall Wace North America's Sorrento Therapeutics, Inc. position peaked at $230K in Q2 2017.
  • 37 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2017.

Based on Marshall Wace North America's 13F filing for Q3 2017, filed 13 Nov 2017.